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BACKGROUND: The molecular mechanisms involved in the genesis of the adrenocortical lesions seen in MEN1
syndrome (ACL-MEN1) remain poorly understood; loss of heterozygosity at 11q13 and somatic mutations of MEN1
are not usually found in these lesions. Thus, additional genes must be involved in MEN1 adrenocortical disorders.
Overexpression of the glucose-dependent insulinotropic peptide receptor has been shown to promote
adrenocortical tumorigenesis in a mice model and has also been associated with ACTH-independent Cushing
syndrome in humans. However, to our knowledge, the status of glucose-dependent insulinotropic peptide receptor
expression in adrenocortical lesions in MEN1 has not been previously investigated.
OBJECTIVE: To evaluate glucose-dependent insulinotropic peptide receptor expression in adrenocortical hyperplasia
associated with MEN1 syndrome.
MATERIALS/METHODS: Three adrenocortical tissue samples were obtained from patients with previously known
MEN1 germline mutations and in whom the presence of a second molecular event (a new MEN1 somatic mutation
or an 11q13 loss of heterozygosity) had been excluded. The expression of the glucose-dependent insulinotropic
peptide receptor was quantified by qPCR using the DDCT method, and b-actin was used as an endogenous control.
RESULTS: The median of glucose-dependent insulinotropic peptide receptor expression in the adrenocortical lesions
associated with MEN1 syndrome was 2.6-fold (range 1.2 to 4.8) higher than the normal adrenal controls (p=0.02).
CONCLUSION: The current study represents the first investigation of glucose-dependent insulinotropic peptide
receptor expression in adrenocortical lesions without 11q13 loss of heterozygosity in MEN1 syndrome patients.
Although we studied a limited number of cases of MEN1 adrenocortical lesions retrospectively, our preliminary data
suggest an involvement of glucose-dependent insulinotropic peptide receptor overexpression in the etiology of
adrenocortical hyperplasia. New prospective studies will be able to clarify the exact role of the glucose-dependent
insulinotropic peptide receptor in the molecular pathogenesis of MEN1 adrenocortical lesions.
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INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1) is a familial
tumor syndrome associated with heterozygous germline
mutations in the MEN1 gene, which encodes a 610-amino-
acid nuclear protein named MENIN.
1,2 Tumors of the
parathyroid glands, the anterior pituitary and the endocrine
pancreas are the lesions more frequently observed in MEN1
syndrome patients; however, more than twenty different
neoplasias in endocrine and non-endocrine tissues have
been associated with MEN1 syndrome.
3 A recent study that
used endoscopic ultrasound has shown that up to 73%
of MEN1 syndrome patients may have small, benign and
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cortical macronodular hyperplasias or adenomas may also
occur in MEN1 syndrome patients, while non-functioning
carcinomas, aldosterone-secreting tumors or pheochromo-
cytomas are rare.
4-8
The MEN1 gene is a typical tumor suppressor gene, and
in accordance with the two-hit hypothesis of Knudson,
9
virtually all MEN1 tumors contain a heterozygous germline
mutation of the MEN1 gene and inactivation of the normal
allele. The combination of the two molecular hits determines
the development of the tumor lesions in MEN1 syn-
drome.
10,11 Recent in vitro studies have demonstrated that
MENIN acts as a transcription factor that can regulate
numerous genes potentially involved in cell cycle control,
including those that encode cyclin-dependent kinase inhi-
bitors (CDKIs), such as p27Kip1 and p18INK4C.
12-14
Nonetheless, the molecular mechanism of the adrenocor-
tical hyperplasia in MEN1 syndrome seems to be different
from the classical MEN1 tumorigenesis, as maintenance of
heterozygosity at the 11q13 locus has been observed.
15-17
Associations between adrenocortical lesions and pancrea-
tic endocrine tumors (PET) in MEN1 syndrome patients
have been observed and may indicate that unknown growth
factor(s) secreted by PETs could play roles in MEN1
adrenocortical lesion development.
7,15,17-19 The gastric inhi-
bitory polypeptide or glucose-dependent insulinotropic
peptide (GIP) might be a candidate to participate in this
process.
Overexpression of glucose-dependent insulinotropic pep-
tide receptor (GIPR) has been demonstrated to be capable of
promoting adrenocortical tumorigenesis in a mice model.
20
In addition, GIPR overexpression has also been associated
with Cushing syndrome resulting from ACTH-independent
macronodular hyperplasia.
21-24 However, the status of GIPR
in ACL-MEN1 remains unknown.
SUBJECTS AND METHODS
Patients and tissue specimens
This study was approved by the Ethics Committee of the
Hospital das Clinicas, Sa ˜o Paulo, Brazil, and written
informed consent was obtained from all patients and
healthy controls. Three unrelated MEN1 syndrome cases
(2 females and 1 male, with an age range of 37 to 59 years)
were studied (Table 1). All cases presented with primary
hyperparathyroidism, enteropancreatic tumors and adreno-
cortical disorder. Case 3 also presented with prolactinoma
and the typical clinical features of hypercortisolism,
whereas patients 1 and 2 had no clinical features of adrenal
hyperfunction. All patients presented a family history
compatible with MEN1 syndrome. The diagnosis of MEN1
syndrome was established according to the NIH MEN
Consensus and molecular findings.
1
Adrenal tumor samples from cases 1 and 2 were obtained
by cutting a biopsy and from case 3 after a bilateral
adrenalectomy, which is recommended for Cushing syn-
drome treatment. Adrenal tissue fragments were immedi-
ately stored in liquid nitrogen until RNA extraction.
Histological data from the adrenal lesions were compatible
with adrenocortical hyperplasia in all cases. Eight normal
human adrenal tissue samples were obtained during
surgical treatment for kidney tumors, and they were used
as normal controls.
MEN1 sequencing
DNA extraction from peripheral leukocytes and tissues
was performed according to standard procedures. For the
synthesis of cDNA, total RNA was isolated from frozen
tissue using TRIzol Reagent (Invitrogen, Carlsbad, CA,
USA). Reverse transcription (RT) was performed using total
RNA from each sample and Multiscribe from a High-
Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA, USA). The protocols for PCR and sequencing
analysis of germline DNA have been previously reported.
25
Exonic primers were used to sequence the entire MEN1
coding region in the cDNA (sequences available upon
request).
LOH analysis
Five MEN1-flanking polymorphic markers (D11S4191,
PYGM, D11S987, D11S527 and D11S937) located at centro-
meric and telomeric regions of the MEN1 gene and covering
the entire 11q12.1-11q14.1 region were used to evaluate loss
of the MEN1 wild-type allele. The LOH analysis protocol
has been previously reported.
26
Forward primers were labeled with fluorescent dyes
(FAM or VIC) that were different from those used in the
internal size standard (TAMRA or ROX-350; Applied
Biosystems). GeneScan software (Applied Biosystems) was
used to analyze the results. When comparing the heights of
the allele peaks in the endocrine tissues (adrenocortical,
parathyroid glands and pancreas) and in the blood samples,
an allelic imbalance ratio of ,0.5 or .2.0 was defined as
LOH.
GIPR expression analysis
Quantitative real-time PCR (qPCR) was performed using
a 7000 real-time PCR System (Applied Biosystems) accord-
ing to the manufacturer’s instructions. TaqMan gene
expression assays were used for GIPR (ID Hs006092_m1)
and b-actin (assay ID-4326315E). The reactions consisted of
12.5 ml of 2X TaqMan Universal PCR master mix, 1.25 mlo f
each 20X assay on demand, 1.5 ml of cDNA and water to
obtain a 25 ml final volume. The PCR parameters were 50˚C
for 2 min, 95˚C for 10 min and 50 cycles at 95˚C for 15 sec









1 59/M Hyperparathyroidism, pancreatic
tumor, bronchopulmonary carcinoid
Non-functioning Hyperplasia 308delC
2 37/F Hyperparathyroidism, pancreatic tumor Non-functioning Hyperplasia W183X
3 37/F Hyperparathyroidism, pancreatic
tumor, prolactinoma
Cushing’s syndrome Hyperplasia 893+1G.A
F- female; M- male.
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530and 60˚C for 1 min. Validation experiments were performed
to confirm that the amplification efficiency of the controls
was similar to that of the target genes.
A cycle threshold (CT) value in the linear range of
amplification was selected for each sample in triplicate and
normalized to b-actin expression levels. The relative
expression levels were analyzed using the 2
2DDCT method,
27
where the DDCT is the difference between the selected DCT
value of a particular sample and the DCT of a pool in 61
normal adrenal glands from autopsies (Clontech, Palo Alto,
CA, USA). The mean expression of the target genes in the
normal adrenal controls was assigned an expression value
of 1.0, and the fold increases in the expression levels were
determined by comparison.
Statistical Analysis
The expression results were compared using the Mann-
Whitney test. The data are presented as the median and
range for each group. The Spearman test was used to
establish correlations between receptor expression, patient
clinical aspects and hormone levels. A p-value ,0.05 was
considered significant.
RESULTS
Status of the MEN1 gene in MEN1 tumors
At least 2 out of the 5 fluorescent polymorphic markers
used in this study were informative for the analysis of the
11q13 LOH in each tumor. Loss of the remaining MEN1 allele
was observed in the pancreatic tumors used as controls,
while no loss was observed in the adrenocortical tumors of
the three patients. cDNA sequences from the ACTs showed
no additional changes (Supplementary Tables 1 and 2).
GIPR expression in MEN1-ACTs
Adrenocortical neoplasias from patients 1, 2 and 3 had
1.2-, 2.6- and 4.8-fold (median 2.6, ranging from 1.2 to 4.8)
higher expression of GIPR as compared with the normal
human adrenocortical tissue (median 0.7, ranging from 0.1
to 1.4) (Figure 1). This finding represents a significantly
increased expression of the GIPR gene in MEN1 adrenocor-
tical neoplasias (p=0.02).
DISCUSSION
Despite the high frequency of adrenocortical lesions in
MEN1 syndrome patients, knowledge of the molecular
pathogenesis of these lesions remains limited. Our data
support the previous findings that, unlike MEN1-related
tumors, ACL-MEN1 tumors do not present loss of hetero-
zygosity at the MEN1 tumor suppressor gene locus, 11q13. In
addition, the possibility of inactivation of the MEN1 wild-
type gene in the hyperplastic adrenal tissue by a de novo
somatic mutation was excluded because no other pathologi-
cal alteration was found by sequencing of the MEN1 cDNA.
Table 2 - GIPR expression in adrenal tissue from 3 patients
with MEN1 syndrome as compared with the normal
human adrenal gland pool (median).
Patient (n) 1 2 3 Normal adrenal tissue
GIPR expression 1.2 2.6 4.8 0.08 to 1.4
Median 2.6 0.7
Figure 1 - GIPR expression in adrenal tissue from 3 patients with MEN1 syndrome as compared with normal human adrenal gland
(median). GIPR expression in all analyzed tissues was 2.6-fold higher than that observed in normal adrenal controls.
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531The frequent association of adrenocortical lesions and
PETs in patients with MEN1 syndrome suggests a common
physiopathological link between both disorders in MEN1
syndrome.
7,15,17,18 Several lines of evidence have led us to
hypothesize that GIP, which stimulates insulin release by
pancreatic b cells, may play a role in MEN1 adrenal
tumorigenesis.
GIP is synthesized and released by the K cells, located in
the duodenum and small intestine after food intake, and
plays an important role in regulating the proliferation and
fate of pancreatic cells.
28,29 Overexpression of GIPR in the
adrenal cortex has been previously demonstrated in patients
with ACTH-independent Cushing syndrome resulting from
food-dependent adrenal cortisol secretion.
21,24,30 GIPR over-
expression has also been identified in adrenocortical
adenomas with androgen or aldosterone hyperproduction
and less frequently in adrenocortical adenomas.
23,31
Recently, one study showed that the aberrant expression
of a non-mutated GIPR gene was sufficient to initiate the
formation of benign adrenocortical tumors and hyperplastic
adrenal tissue using an in vivo cell transplantation model in
mice.
20
The potential involvement of the GIPR gene in the
etiology of adrenocortical hyperplasia occurring in MEN1
syndrome might be supported by this evidence. Although a
small number of adrenal samples were analyzed, our data
demonstrated a previously unknown overexpression of this
gene in ACL-MEN1. Using normal human adrenal tissue as
a reference for the expression assays, our results indicated a
significantly higher expression of GIPR in all three samples
of the MEN1 adrenal tissue; on average, it was 2.6-fold
higher than in normal adrenal glands.
As the GIPR is a transmembrane receptor coupled to the
adenyl cyclase/cAMP signaling cascade, its overexpression
may lead to disruption of the cAMP pathway. Deregulation
of cAMP has been reported in sporadic adrenocortical
tumors and attributed to mutations in the PRKAR1A,
GNAS1, PDE11A and PDE8B genes,
32-35 but not in the
GIPR.
36 Unfortunately, we were not able to perform cAMP
measurements in the adrenocortical tissues that over-
expressed GIPR.
In vitro, overexpression of the GIPR agonist (GIP) has
been associated with both hormonogenesis and cell pro-
liferation because it increases cAMP production and the
synthesis of DNA in the GIP-dependent, cortisol-secreting
adenoma cells.
37 Our data indicate that, as in ACTH-
independent macronodular adrenal hyperplasia, GIPR may
play a role in the cellular proliferation of adrenocortical
hyperplasia occurring in MEN1 syndrome.
Because the investigative protocol was developed after
adrenal surgery, we do not have data regarding the
cortisol response to food intake in these MEN1 syndrome
patients.
In conclusion, knowledge regarding the genesis of the
frequent adrenal lesions observed in MEN1 syndrome
patients remains limited. The current study represents
the first investigation of GIPR in MEN1 human adreno-
cortical lesions without 11q13 LOH and suggests a
potential role of GIPR overexpression in the development
of the adrenocortical lesions associated with MEN1
hyperplasia. New prospective studies will be able to
clarify the exact role of GIPR in the molecular pathogen-
esis of ACL-MEN1.
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Supplementary Table 2 - MEN 1 mutations identified in








1 308delC 308delC 308delC NA
2 W183X W183X W183X W183X
3 893+1G.A 893+1G.A 893+1G.A 893+1G.A
NA, not available.
Supplementary Table 1- Allelic distribution of the five
microsatellite markers used in the LOH study of MEN1
syndrome patients.
Patients Tissues D11S4191 PYGM D11S987 D11S527 D11S937
1 Blood 89/91 169/171 120/120 142/159 152/160
Adrenal 89/91 169/171 120/120 142/159 152/160
2 Blood 97/119 167/173 120/122 147/157 160/160
Adrenal - 167/173 120/122 - 160/160
Pancreatic 97 167 120 147 160/160
3 Blood 95/107 175/183 116/116 143/145 156/160
Adrenal D 95/107 175/183 116/116 143/145 156/160
Adrenal E 95/107 175/183 116/116 143/145 156/160
Pancreatic 95 183 116/116 143 156
(-) blank spaces indicate unavailable sample material.
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